Calithera initiates phase 1/2 trial of Telaglenastat in combination with PARP inhibitor
Calithera Biosciences announced the first patient has been treated in the Phase 1/2 open-label clinical trial of the glutaminase inhibitor telaglenastat (CB-839) in combination with Pfizer's poly adenosine diphosphate ribose polymerase inhibitor talazoparib, also known as Talzenna®.
March 26, 2019